Meritorious Home Care, Inc. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 7204 Whitetail Dr, Julian, NC 27283 Phone: 336-892-5031 |
News Archive
Trubion Pharmaceuticals, Inc. today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.
Mass. Gov. Deval Patrick says he wants new legislation by the end of the month to strengthen security around clinics. Missouri Gov. Jay Nixon vetoed a bill that would require women to wait 72 hours for the procedure.
A newly published paper describes and evaluates the Indiana University Center for Health Innovation and Implementation Science, a novel virtual laboratory employing the tools of implementation science to improve population health, lower costs of its delivery and prepare the future health care transformational leaders.
The surface of your skin, called the epidermis, is a complex mixture of many different cell types - each with a very specific job. The production, or differentiation, of such a sophisticated tissue requires an immense amount of coordination at the cellular level, and glitches in the process can have disastrous consequences. Now, researchers at the Stanford University School of Medicine have identified a master regulator of this differentiation process.
The World Health Organisation (WHO) says a vaccine against the killer H5N1 bird flu virus could be licensed for humans within a year.
› Verified 9 days ago